Bavarian Nordic announces commercial availability of VAXCHORA in Canada
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 16 2024
0mins
VAXCHORA Availability: Bavarian Nordic has announced the commercial availability of VAXCHORA, the only single-dose oral cholera vaccine approved in Canada, which provides protection within 10 days after administration.
Cholera Impact and Transmission: Cholera is a serious intestinal infection endemic to about 50 countries, with an estimated 1.3 million to 4 million cases globally each year, primarily transmitted through contaminated water and food.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
